News - Vivus, Qsymia


Current filters:


Popular Filters

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients


New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…


Market for obesity therapies to reach a value of $2.6 billion in 2019


The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report


The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Law suit threat for Vivus over battle for shareholders' votes


The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest


US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…


It's official: "obesity is a disease," says AMA


The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus rises as FDA eases restrictions on diet pill Qsymia


USA drugmaker Vivus' (Nasdaq: VVUS) shares rose as much as 11% by traded up 5% at $11.69, after the company…

MetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia


US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to…


Express Scripts adds Vivus' Qsymia to its standard benefits program


US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA's largest Pharmacy Benefit…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts


Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release)…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus debuts weight-loss pill Qsymia on US market


USA-based Vivus (Nasdaq: VVUS) saw its shares rise 3.9% to $22.93 on Monday, after the company announced…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment


Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight…

Arena PharmaceuticalsBelviqMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

US FDA approves second diet pill, Vivus' Qsymia


In a much anticipated but largely expected decision, the US Food and Drug Administration yesterday approved…

MetabolicsNorth AmericaPharmaceuticalQnexaQsymiaRegulationVivus

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top